Identification of genetic variation exclusive to specific lineages associated with Staphylococcus aureus bacteraemia

The Journal of Hospital Infection
D PatelMeeta Desai

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia cases have declined since 2003, and have mostly been due to two epidemic (E) strains, E15 (multi-locus sequence type clonal complex CC22) and E16 (CC30). By contrast, the incidence of meticillin-susceptible S. aureus (MSSA) bacteraemia has remained largely unchanged and our understanding of these isolates has remained poor. To investigate the distribution and nucleotide sequence of heterogeneous regions between successful lineages using the 2009 British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Resistance Surveillance Programme collection of S. aureus. S. aureus isolates (N = 202) comprised of 103 MRSA and 99 MSSA isolates were analysed using fluorescent amplified fragment length polymorphism (FAFLP) to detect nucleotide variations due to lineage-specific sequence motifs as well as differences in the distribution of mobile genetic elements between lineages. E15 and E16 MRSA strains comprised 79% and 6% of the collection in 2009 respectively. Six lineages, including CC22 and CC30, were associated with MRSA bacteraemia in the UK and Ireland. MSSA isolates were more diverse with 19 different lineages detected. FAFLP revealed lineage-specific sequence var...Continue Reading

References

Nov 11, 1995·Nucleic Acids Research·P VosM Kuiper
Jul 1, 1996·FEMS Microbiology Reviews·T Gonzales, J Robert-Baudouy
Feb 24, 2001·Cellular and Molecular Life Sciences : CMLS·E RauxM J Warren
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mark C EnrightBrian G Spratt
Oct 16, 2003·Current Opinion in Pharmacology·Mark C Enright
Nov 18, 2003·Journal of Bacteriology·Christian KohlerSusanne Engelmann
Nov 26, 2003·Antimicrobial Agents and Chemotherapy·D Ashley Robinson, Mark C Enright
Jul 28, 2005·The Journal of Antimicrobial Chemotherapy·Alan P JohnsonGeorgia Duckworth
Jan 31, 2006·Hemodialysis International·Mark D DaneseAllen R Nissenson
Sep 28, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S PlattJ Green
Apr 21, 2007·Journal of Medical Microbiology·Joshua D CockfieldJodi A Lindsay
Jun 20, 2007·Antimicrobial Agents and Chemotherapy·Catarina MilheiriçoHermínia de Lencastre
Jul 29, 2008·Nucleic Acids Research·Masayoshi HondaTsutomu Mikawa
Sep 30, 2008·Journal of Bacteriology·Steffen SchlagFriedrich Götz
Dec 1, 2009·Nature Reviews. Microbiology·Michael E HibbingS Brook Peterson
Dec 26, 2009·The Journal of Antimicrobial Chemotherapy·Matthew J EllingtonAlan P Johnson
Aug 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Zheyun LiuDongping Zhong

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.